THERAPEUTICS
Intensive and standard glucose control did not differ for CV events or death in poorly controlled type 2 diabetes
| The first 150 words of the full text of this article appear below. |
STUDY DESIGN
randomised controlled trial (Veterans Affairs Diabetes Trial [VADT]). ClinicalTrials.gov NCT00032487 [ClinicalTrials.gov] .
unclear allocation concealment.*
blinded (outcome assessors).*
STUDY QUESTION
20 sites in the USA.
1791 patients (mean age 60 y, 97% men) who had inadequate responses to maximum doses of an oral agent or insulin therapy. Exclusion criteria included glycated haemoglobin (HbA1c) concentration <7.5%, cardiovascular (CV) event in the past 6 months, advanced congestive heart failure (CHF), severe angina, body mass index (BMI) >40 kg/m2, serum creatinine concentration >1.6 mg/dl (141 µmol/l), and alanine aminotransferase concentration >3 times the upper normal limit.
intensive (n = 892) or standard glucose control (n = 899). Patients were given oral metformin plus rosiglitazone (BMI
27 kg/m2) or oral glimepiride plus rosiglitazone (BMI <27 kg/m2). The intensive-control group started with maximum doses, and the standard-control group started with half-maximum doses. Patients in the intensive-control group who did not achieve HbA1c concentrations <6%
St Michael's Hospital, University of Toronto Toronto, Ontario, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
